<DOC>
	<DOCNO>NCT01412281</DOCNO>
	<brief_summary>The purpose study assess humoral immune response safety parenteral formulation 2010/2011-season virosomal subunit influenza vaccine Inflexal V use two different HA antigen supplier ( AdImmune CSL ) , group young elderly adult , use EMA ( European Medicines Agency ) regulation guideline .</brief_summary>
	<brief_title>Immunogenicity Safety Study Assess Influenza Vaccine Formulated With Haemagglutinin ( HA ) Antigen From Two Different Suppliers</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy female male adult Aged ≥18 year Day 1 Written inform consent Acute exacerbation bronchopulmonary infection ( cough , sputum , lung finding ) acute disease Acute febrile illness ( ≥38.0 °C ) Prior vaccination influenza vaccine ( include H1N1 pandemic swine flu vaccine ) past 330 day Known hypersensitivity vaccine component Previous history serious adverse reaction influenza vaccine History egg protein allergy severe atopy Known blood coagulation disorder Chronic ( longer 14 day ) administration immunosuppressant immunemodifying drug within 6 month first dose study vaccine , incl . oral corticosteroid dosage ≥0.5 mg/kg/d prednisolone equivalent ( inhaled topical steroid allow ) Known immunodeficiency ( incl . leukemia , cancer , HIV seropositivity ) Investigational medicinal product receive past 3 month ( 90 day ) Treatment immunoglobulin blood transfusion ( ) receive past 3 month ( 90 day ) Pregnancy lactation Participation another clinical trial Employee investigational site , spouse child investigator , relative living household investigator and/or dependent investigator Suspected noncompliance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Virus</keyword>
	<keyword>Vaccination</keyword>
	<keyword>Immunisation</keyword>
</DOC>